CA3224271A1 - Cannabidiolic acid esters for treating prader-willi syndrome - Google Patents
Cannabidiolic acid esters for treating prader-willi syndrome Download PDFInfo
- Publication number
- CA3224271A1 CA3224271A1 CA3224271A CA3224271A CA3224271A1 CA 3224271 A1 CA3224271 A1 CA 3224271A1 CA 3224271 A CA3224271 A CA 3224271A CA 3224271 A CA3224271 A CA 3224271A CA 3224271 A1 CA3224271 A1 CA 3224271A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- use according
- cbda
- group
- cannabinoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221006P | 2021-07-13 | 2021-07-13 | |
| US63/221,006 | 2021-07-13 | ||
| US202163276668P | 2021-11-08 | 2021-11-08 | |
| US63/276,668 | 2021-11-08 | ||
| PCT/IL2022/050734 WO2023286047A1 (en) | 2021-07-13 | 2022-07-07 | Cannabidiolic acid esters for treating prader-willi syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3224271A1 true CA3224271A1 (en) | 2023-01-19 |
Family
ID=84919088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3224271A Pending CA3224271A1 (en) | 2021-07-13 | 2022-07-07 | Cannabidiolic acid esters for treating prader-willi syndrome |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240316073A1 (https=) |
| EP (1) | EP4370106A4 (https=) |
| JP (1) | JP2024528569A (https=) |
| AU (1) | AU2022312764A1 (https=) |
| CA (1) | CA3224271A1 (https=) |
| IL (1) | IL310009A (https=) |
| WO (1) | WO2023286047A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3062814C (en) * | 2017-04-27 | 2023-11-14 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| US12403114B2 (en) * | 2019-03-12 | 2025-09-02 | Epm (Ip), Inc. | Cannabinoid acid ester compositions and uses thereof |
| WO2021137224A1 (en) * | 2020-01-01 | 2021-07-08 | Epm Group, Inc. | Cannabidiolic acid esters for treating muscular dystrophy |
| CN113087599A (zh) * | 2020-01-08 | 2021-07-09 | 成都百裕制药股份有限公司 | 大麻二酚衍生物及其制备方法和在医药上的应用 |
-
2022
- 2022-07-07 JP JP2024500204A patent/JP2024528569A/ja active Pending
- 2022-07-07 WO PCT/IL2022/050734 patent/WO2023286047A1/en not_active Ceased
- 2022-07-07 US US18/574,167 patent/US20240316073A1/en active Pending
- 2022-07-07 CA CA3224271A patent/CA3224271A1/en active Pending
- 2022-07-07 IL IL310009A patent/IL310009A/en unknown
- 2022-07-07 AU AU2022312764A patent/AU2022312764A1/en active Pending
- 2022-07-07 EP EP22841608.7A patent/EP4370106A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL310009A (en) | 2024-03-01 |
| JP2024528569A (ja) | 2024-07-30 |
| AU2022312764A1 (en) | 2024-01-18 |
| US20240316073A1 (en) | 2024-09-26 |
| WO2023286047A1 (en) | 2023-01-19 |
| EP4370106A1 (en) | 2024-05-22 |
| EP4370106A4 (en) | 2025-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260027079A1 (en) | Cannabinoid acid ester compositions and uses thereof | |
| JP5308160B2 (ja) | 前立腺疾病及び皮膚癌におけるイソチオシアネート系化合物の使用 | |
| BR112015015870B1 (pt) | Uso de uma composição farmacêutica | |
| JP3114895B2 (ja) | 炎症性疾患の処置のための薬剤調製物 | |
| WO2022103636A1 (en) | Improved use of cannabinoids in the treatment of alzheimer's disease | |
| CN102274227B (zh) | 粉防己碱在制备预防和/或治疗抑郁症药物中的应用 | |
| JP2004532271A (ja) | リパーゼ阻害剤とショ糖脂肪酸エステルとを含む医薬組成物 | |
| US20240092797A1 (en) | Methods of making low odor choline salts of an organic compound | |
| WO2020077915A1 (zh) | 羟基酪醇及其衍生物在制备抗抑郁产品中的新应用 | |
| WO2021224924A1 (en) | Cannabidiolic acid esters for treating respiratory distress including acute respiratory distress syndrome and coronavirus | |
| US20240316073A1 (en) | Cannabidiolic acid esters for treating prader-willi syndrome | |
| CN117813081A (zh) | 用于治疗普拉德-威利综合征的大麻二醇酸酯 | |
| HK40107023A (zh) | 用於治疗普拉德-威利综合征的大麻二醇酸酯 | |
| WO2021137224A1 (en) | Cannabidiolic acid esters for treating muscular dystrophy | |
| TW202320800A (zh) | 神經活性類固醇之結晶形式 | |
| Mustafa et al. | Venlafaxine loaded novasomes for intranasal delivery: Mucoadhesion, permeation and pharmacokinetics study | |
| CN101967174B (zh) | 一种环木菠萝烯醇阿魏酸酯的组合物制剂和纯化工艺 | |
| ES3002660T3 (en) | Crystalline forms of beta-sitosterol | |
| CN118924714B (zh) | 一种含mk-7药物组合物及其应用和制备方法 | |
| CN101590008B (zh) | 一种24-亚甲基环木菠萝醇阿魏酸酯的组合物制剂和纯化工艺 | |
| JP2001506628A (ja) | 抗酸化剤としてのエキレニンの使用 | |
| RU2795027C2 (ru) | Фармацевтический препарат | |
| CN110882241B (zh) | 萜内酯化合物改善胃粘膜损伤的用途 | |
| CN118786134A (zh) | Dhea衍生的类固醇 | |
| WO2010136592A1 (en) | Derivatives of ursodeoxycholic acid for the treatment of diarrhoea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250626 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250626 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260312 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260312 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260324 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260324 |